GlassScriptPhysician profile
Paul Hriso
NPI 1295754158
$8,470.24
in general payments reported to CMS, 2019-2025
33 companies · $1,402 in 2025
The $1,402 reported for 2025 was more than what 85% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,058 · 2020: $998 · 2021: $1,784 · 2022: $553 · 2023: $1,314 · 2024: $1,361 · 2025: $1,402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,065 · Education: $13.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,064.79 |
| Education | $13.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,384.36 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $752.05 | 2020-2025 | Caplyta |
| Lundbeck LLC | $563.84 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $534.27 | 2019-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $531.47 | 2021-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $501.05 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Bausch Health US, LLC | $490.26 | 2019-2025 | Aplenzin, Wellbutrin |
| Axsome Therapeutics, INC. | $472.11 | 2023-2025 | Sunosi, Auvelity |
| Teva Pharmaceuticals USA, INC. | $405.71 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $401.48 | 2019-2025 | Trintellix |
| Allergan, INC. | $326.59 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $318.68 | 2019-2022 | |
| Tris Pharma INC | $239.14 | 2023-2025 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $235.99 | 2019-2023 | Invega Sustenna, Invega Trinza, Spravato |
| Idorsia Pharmaceuticals US INC | $225.98 | 2023-2024 | Quviviq |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $203.64 | 2019-2022 | |
| Eisai INC. | $137.81 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $134.31 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $129.75 | 2020-2021 | |
| Almatica Pharma LLC | $69.12 | 2023-2025 | Loreev Xr, Sertraline Hcl |
| Supernus Pharmaceuticals, INC. | $53.03 | 2021-2023 | Qelbree |
| Shire North American Group INC | $52.07 | 2019 | |
| Neos Therapeutics, LP | $46.06 | 2023-2024 | Adzenys Xr-Odt |
| E.R. Squibb & Sons, L.L.C. | $45.28 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $40.93 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $30.58 | 2025 | Jornay Pm |
| Adlon Therapeutics L.P. | $30.02 | 2019-2020 | |
| Noven Therapeutics, LLC | $29.85 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $27.91 | 2019 | |
| Corium, LLC | $16.35 | 2024 | Azstarys |
| Validus Pharmaceuticals LLC | $16.10 | 2025 | Equetro, Raldesy |
| Ironshore Pharmaceuticals INC. | $14.43 | 2019 | |
| Neuronetics, INC. | $10.02 | 2023 | Neurostar Tms Therapy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Hriso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.